Back to search results

Stephanie Christenson, MD, MS

Chronic Obstructive Pulmonary Disease

Lung Health Center at Parnassus
400 Parnassus Ave., Sixth Floor, Room A6114,
San Francisco, CA 94143

Virtual visits available

Lung Health Center at Parnassus
400 Parnassus Ave., Sixth Floor, Room A6114,
San Francisco, CA 94143

About me

Insurance plan info

Dr. Stephanie Christenson cares for patients in the intensive care unit as well as patients with lung disease in the clinic.

In her research, Christenson uses gene-analyzing technologies to identify patients with asthma or chronic obstructive pulmonary disease who may respond better to specific therapies based on their underlying biology.

Christenson earned her medical degree from the Medical College of Wisconsin. She completed a residency in internal medicine at Boston University School of Medicine. At UCSF, she completed a fellowship in pulmonary and critical care medicine and a master of advanced study degree in clinical research.

Christenson is a member of the American Thoracic Society.

Board Certifications

American Board of Internal Medicine, Critical Care Medicine
American Board of Internal Medicine, Pulmonary Disease
Fellowships

UCSF, Pulmonary, Critical Care, and Sleep Medicine
Residencies

Boston Medical Center, Internal Medicine
Internship

Boston Medical Center, Internal Medicine
Degree

MD, Medical College of Wisconsin

Where I see patients (1)

Selected research

See all research

Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation.
Science translational medicine
August 2025
Learn more
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial.
The Lancet. Respiratory medicine
July 2025
Learn more
Omic Risk Scores are Associated with COPD-related Traits Across Three Cohorts.
medRxiv : the preprint server for health sciences
June 2025
Learn more

Clinical trials

See all clinical trials

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

To determine the efficacy of omalizumab injection in reducing the annualized rate of moderate or severe exacerbations (primary outcome) over the course of 12 months among individuals with COPD having sensitization and exposure to ...

Recruiting

American Lung Association (ALA) Lung Health Cohort

Pre-bronchodilator measurements of FEV1 to determine bronchoconstriction. FEV1 is measured in liters of air. Severity of bronchoconstriction is based on predicted values published by National Health and Nutrition Examination Surve...